Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kymera Therapeutics, Inc.KYMR · Entity 3545 | Chief Business Officer | July 01, 2026 | July 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kymera Therapeutics, Inc.
Report date July 01, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 47,179.438 |
Reported balance
After 2026-07-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-01 · Sale · Disposed 3,389 · Balance 47,179.438 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. F2: This number includes 373 shares acquired under the Registrant's employee stock purchase plan. |
Filing footnotes · ownership attribution and instrument terms
F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person.
F2: This number includes 373 shares acquired under the Registrant's employee stock purchase plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2026 Filed Jul 2, 2026 22:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 3,389 | $114.29 | $387,328.81 |
DisclosureSEC source: 0001193125-26-295089 · ownership.xml · nonDerivative · entry 1 Goodman Noah · CIK 0002060075 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,179.438 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. F2 · balance_after: This number includes 373 shares acquired under the Registrant's employee stock purchase plan. Read SEC document |
| June 25, 2026 Filed Jun 25, 2026 22:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $21.05 | $0.00 |
DisclosureSEC source: 0001193125-26-283139 · ownership.xml · derivative · entry 4 Goodman Noah · CIK 0002060075 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 5,000 shares Expires 2035-04-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this stock option vested on April 8, 2026, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| June 25, 2026 Filed Jun 25, 2026 22:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 2,500 | $119.00 | $297,500.00 |
DisclosureSEC source: 0001193125-26-283139 · ownership.xml · nonDerivative · entry 3 Goodman Noah · CIK 0002060075 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,195.438 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. Read SEC document |
| June 25, 2026 Filed Jun 25, 2026 22:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 2,500 | $109.00 | $272,500.00 |
DisclosureSEC source: 0001193125-26-283139 · ownership.xml · nonDerivative · entry 2 Goodman Noah · CIK 0002060075 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,695.438 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. Read SEC document |
| June 25, 2026 Filed Jun 25, 2026 22:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 5,000 | $21.05 | $105,250.00 |
DisclosureSEC source: 0001193125-26-283139 · ownership.xml · nonDerivative · entry 1 Goodman Noah · CIK 0002060075 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,195.438 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. Read SEC document |
| June 22, 2026 Filed Jun 22, 2026 21:47 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $21.05 | $0.00 |
DisclosureSEC source: 0001193125-26-277766 · ownership.xml · derivative · entry 3 Goodman Noah · CIK 0002060075 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 2,500 shares Expires 2035-04-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this stock option vested on April 8, 2026, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| June 22, 2026 Filed Jun 22, 2026 21:47 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 2,500 | $99.00 | $247,500.00 |
DisclosureSEC source: 0001193125-26-277766 · ownership.xml · nonDerivative · entry 2 Goodman Noah · CIK 0002060075 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,195.438 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. Read SEC document |
| June 22, 2026 Filed Jun 22, 2026 21:47 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 2,500 | $21.05 | $52,625.00 |
DisclosureSEC source: 0001193125-26-277766 · ownership.xml · nonDerivative · entry 1 Goodman Noah · CIK 0002060075 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,695.438 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. Read SEC document |
| April 14, 2026 Filed Apr 16, 2026 22:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 1,347 | $90.00 | $121,230.00 |
DisclosureSEC source: 0001193125-26-159539 · ownership.xml · nonDerivative · entry 1 Goodman Noah · CIK 0002060075 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,195.438 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. Read SEC document |
| April 10, 2026 Filed Apr 10, 2026 20:45 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 2,000 | $87.35 | $174,700.00 |
DisclosureSEC source: 0001193125-26-151393 · ownership.xml · nonDerivative · entry 5 Goodman Noah · CIK 0002060075 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,542.438 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. Read SEC document |
| April 09, 2026 Filed Apr 10, 2026 20:45 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $21.05 | $0.00 |
DisclosureSEC source: 0001193125-26-151393 · ownership.xml · derivative · entry 6 Goodman Noah · CIK 0002060075 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 97,500 Underlying: Common Stock · 2,500 shares Expires 2035-04-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. F5 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this stock option vested on April 8, 2026, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| April 09, 2026 Filed Apr 10, 2026 20:45 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 2,500 | $89.00 | $222,500.00 |
DisclosureSEC source: 0001193125-26-151393 · ownership.xml · nonDerivative · entry 4 Goodman Noah · CIK 0002060075 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,542.438 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. Read SEC document |
| April 09, 2026 Filed Apr 10, 2026 20:45 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 2,670 | $87.11 | $232,586.10 |
DisclosureSEC source: 0001193125-26-151393 · ownership.xml · nonDerivative · entry 3 Goodman Noah · CIK 0002060075 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,042.438 F2 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.015 to $87.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 09, 2026 Filed Apr 10, 2026 20:45 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 3,094 | $86.62 | $267,996.09 |
DisclosureSEC source: 0001193125-26-151393 · ownership.xml · nonDerivative · entry 2 Goodman Noah · CIK 0002060075 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,712.438 F2 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.005 to $86.935, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 09, 2026 Filed Apr 10, 2026 20:45 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 2,500 | $21.05 | $52,625.00 |
DisclosureSEC source: 0001193125-26-151393 · ownership.xml · nonDerivative · entry 1 Goodman Noah · CIK 0002060075 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,806.438 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 23:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantStock Option (Right to Buy) · Derivative | 18,450 | $0.00 Strike: $90.10 | $0.00 |
DisclosureSEC source: 0001193125-26-091984 · ownership.xml · derivative · entry 2 Goodman Noah · CIK 0002060075 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,450 Underlying: Common Stock · 18,450 shares Expires 2036-03-01 F2 · derivative.exercise_date: The shares underlying this stock option shall vest in fourty-eight (48) equal monthly installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 23:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantCommon Stock | 9,225 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-091984 · ownership.xml · nonDerivative · entry 1 Goodman Noah · CIK 0002060075 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,306.438 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| April 08, 2025 Filed Apr 9, 2025 12:05 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $21.05 | $0.00 |
DisclosureSEC source: 0000950170-25-052310 · ownership.xml · derivative · entry 2 Goodman Noah · CIK 0002060075 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2035-04-07 F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this stock option shall vest on April 8, 2026, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| April 08, 2025 Filed Apr 9, 2025 12:05 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-052310 · ownership.xml · nonDerivative · entry 1 Goodman Noah · CIK 0002060075 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,081.438 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following April 8, 2025, subject to the reporting person's continued employment through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.